Recent Company News

• 10:12 PM ET Aug 20, 2025
  

  RBC Capital Markets transfers ALM.SM, BIOA.B.SS, FYB.GR, others

• 11:09 PM ET Aug 18, 2025
  

  Singapore approves Beyfortus (nirsevimab) for prevention of RSV in newborns and infants (€85.58, 0.00)

• 07:27 PM ET Jul 28, 2025
  

  FDA approves Apellis Pharmaceuticals' EMPAVELI (pegcetacoplan) as first treatment for C3G or primary IC-MPGN in patients 12 years and older to reduce proteinuria ($18.75, 0.00)

• 07:51 AM ET Jul 25, 2025
  

  Swedish Orphan Biovitrum notes Tryngolza (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (SEK 282.80, +0.40)

• 07:02 AM ET Jul 25, 2025
  

  Sobi Announces FDA Approves Doptelet (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP) (SEK 282.60, +0.20)

• 05:30 AM ET Jul 16, 2025
  

  Street Takeaways - Swedish Orphan Biovitrum Q2 earnings (SEK 285.40, -8.80)

• 02:12 AM ET Jul 16, 2025
  

  StreetAccount Metrics Recap - Swedish Orphan Biovitrum Q2 Earnings (SEK 294.20, 0.00)

• 02:05 AM ET Jul 16, 2025
  

  Swedish Orphan Biovitrum reports Q2 adj EPS SEK2.36 vs consensus SEK1.68; keeps FY25 outlook unchanged (SEK 294.20, 0.00)

• 01:21 PM ET Jul 15, 2025
  

  Swedish Orphan Biovitrum to repurchase all class C shares (SEK 294.20, 0.00)

• 06:34 AM ET Jul 15, 2025
  

  StreetAccount Consensus Metrics Preview - Swedish Orphan Biovitrum Q2 Earnings (SEK 298.60, +3.20)